185 related articles for article (PubMed ID: 7749147)
1. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
[TBL] [Abstract][Full Text] [Related]
2. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
Int J Cancer; 1997 Jul; 72(3):416-23. PubMed ID: 9247284
[TBL] [Abstract][Full Text] [Related]
3. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
[TBL] [Abstract][Full Text] [Related]
4. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.
Rosenquist C; Thorpe SM; Danø K; Grøndahl-Hansen J
Breast Cancer Res Treat; 1993 Dec; 28(3):223-9. PubMed ID: 8018952
[TBL] [Abstract][Full Text] [Related]
6. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Pedersen AN; Høyer-Hansen G; Brünner N; Clark GM; Larsen B; Poulsen HS; Danø K; Stephens RW
J Immunol Methods; 1997 Apr; 203(1):55-65. PubMed ID: 9134030
[TBL] [Abstract][Full Text] [Related]
7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
8. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
12. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Qin W; Zhu W; Wagner-Mann C; Folk W; Sauter ER
Cancer J; 2003; 9(4):293-301. PubMed ID: 12967140
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
16. Correlation of tissue and blood plasminogen activation system in breast cancer.
Rha SY; Yang WI; Gong SJ; Kim JJ; Yoo NC; Roh JK; Min JS; Lee KS; Kim BS; Chung HC
Cancer Lett; 2000 Mar; 150(2):137-45. PubMed ID: 10704735
[TBL] [Abstract][Full Text] [Related]
17. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Rønne E; Behrendt N; Ploug M; Nielsen HJ; Wöllisch E; Weidle U; Danø K; Høyer-Hansen G
J Immunol Methods; 1994 Jan; 167(1-2):91-101. PubMed ID: 8308290
[TBL] [Abstract][Full Text] [Related]
19. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
20. Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.
Bouchet-Bernet C; Spyratos F; Andrieu C; Deytieux S; Bécette V; Oglobine J
Breast Cancer Res Treat; 1996; 41(2):141-6. PubMed ID: 8944332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
